Correspondence 0001641172-25-003405 from LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Date: April 9, 2025 · CIK: 0001335105 · Accession: 0001641172-25-003405
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286385
Letter
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
East Colorado Boulevard, Suite 180
Pasadena, California 91101
April 9, 2025
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F. Street, N.E.
Washington, D.C. 20549
Re: Lixte Biotechnology Holdings, Inc.
Registration Statement on Form S-1
File No. 333-286385
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Lixte Biotechnology Holdings, Inc., a Delaware corporation, respectfully requests that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 5:00 p.m., Eastern Time, on Thursday, April 10, 2025, or as soon thereafter as is practicable. Please call our counsel, David Ficksman of TroyGould PC at 818 469 4200 to provide notice of effectiveness.
Very
truly yours,
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
Show Raw Text
CORRESP 1 filename1.htm LIXTE BIOTECHNOLOGY HOLDINGS, INC. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 April 9, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Lixte Biotechnology Holdings, Inc. Registration Statement on Form S-1 File No. 333-286385 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Lixte Biotechnology Holdings, Inc., a Delaware corporation, respectfully requests that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 5:00 p.m., Eastern Time, on Thursday, April 10, 2025, or as soon thereafter as is practicable. Please call our counsel, David Ficksman of TroyGould PC at 818 469 4200 to provide notice of effectiveness. Very truly yours, LIXTE BIOTECHNOLOGY HOLDINGS, INC. By: /s/ Bas van der Baan Bas van der Baan Chief Executive Officer